In this podcast, we interviewed Dr. Yuyi Shen about the benefits of modeling disruptive technologies to improve downstream bioprocessing and evaluating the financial impact of implementing these technologies.<br />
View show notes at downstreamcolumn.com/podcast/modeling-downstream-disruptive-technologies-to-improve-downstream-bioprocessing/

Start With The End In Mind. How to facilitate transfer from non-GMP to GMP Manufacturing

The Downstream Column (DsC) is an online publication targeting members of the biologics industry. Our intent is to provide a community to share expertise and best practices as well as discuss topics of interest. The Downstream Column covers areas important to the research, discovery, development, and manufacture of biologic therapeutics. Key industry coverage areas include: purification, formulation, fill/finish and QA/QC for cell and gene therapies, vaccines, biologics, and emerging therapeutic modalities.